Utilizing Different Mechanisms of Action for Treatment of Chronic Graft-Versus-Host Disease
January 9th 2024Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss current and emerging treatment landscape of chronic graft-versus-host disease (GVHD). They examine treatment selection in different lines of therapies and the near future landscape of treatment when newer mechanisms of action become available for GVHD.
Advancements in the Treatment of Desmoid Tumors
December 13th 2023A panel of expert oncologists explore recent advancements in the treatment of desmoid tumors, highlighting the approval of nirogacestat as the first FDA-approved in this treatment setting, and discussing its impact on clinical practice.
ESMO 2023: Expert Perspectives & Insights into the Testing and Treatment of Melanoma
October 31st 2023A panel of experts discusses updates in metastatic melanoma biomarker testing and treatment presented at ESMO Congress 2023 and other recent meetings and reviews the data in the context of existing guidelines, the current treatment landscape, and its impact on clinical practice.
Optimizing Homologous Recombination Deficiency (HRD) Testing Paradigms in Ovarian Cancer
July 17th 2023Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD discuss the biological mechanisms behind homologous recombination deficiency (HRD) in ovarian cancer and expand on best practices for somatic and germline HRD testing and results-based patient management in the clinic.
HER2+ Breast Cancer: Recent Data Updates and Key Advances
June 29th 2023A panel of experts summarizes the current treatment landscape for early and metastatic HER2+ breast cancer and discusses recent data updates in these settings, including those presented at the 2023 American Society of Clinical Oncology (ASCO) meeting.